Bleomycin electrosclerotherapy for slow-flow vascular malformations
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a treatment called bleomycin electrosclerotherapy for people with slow-flow vascular malformations (abnormal blood vessels that do not flow quickly). The goal is to see if this treatment works well and is safe for these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be scheduled to have this treatment as part of your regular medical care.
- You must have a diagnosis of a slow-flow vascular malformation that was confirmed by an MRI with contrast within the last 6 months.
- You have not had any invasive treatment for your vascular malformation in the last 6 months, such as surgery, sclerotherapy, or laser treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment called bleomycin electrosclerotherapy (BEST) for people with low-flow vascular malformations—abnormal clusters of blood or lymph vessels that can cause pain or swelling. The treatment combines a drug (bleomycin) with a small electrical current to shrink these abnormal vessels, and the goal is to see if it helps when other treatments haven't worked well or the problem came back.
This study is testing a treatment called electrosclerotherapy for low-flow venous malformations. It uses a medicine (bleomycin) injected into the abnormal blood vessels to shrink them. The goal is to see how well it works and how safe it is.
This trial tests two targeted medicines for people with certain types of vascular malformations (abnormal blood vessels). If you have a slow-flow malformation, you may receive alpelisib; if you have a fast-flow malformation, you may receive mirdametinib. Genetic testing is needed to see if your malformation has a specific change that these drugs target.
This study tests a treatment that uses microwave energy to shrink painful or troublesome abnormal blood vessels (vascular malformations). It may help reduce symptoms like pain and swelling without open surgery.
This trial tests a pill called everolimus to see if it can shrink or control abnormal blood vessel growths (vascular anomalies) that have not responded to other treatments. It may offer a new option for patients aged 1 year and older.
This Phase 3 study tests whether sirolimus helps control complex vascular anomalies that have not responded to standard treatments. It also checks safety by monitoring blood tests, organ function, and overall health during treatment.
Hear when a new Vascular Malformations trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.